Valuation
- Market cap
- 100,813,000
- Revenue TTM
- $65,300,000
- Net income TTM
- $17,780,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 27.23%
- Debt to equity
- 0.00
Trading
- Volume
- 4,033,000
- Avg volume
- 1,770,890
- Day's range
- $2.85 – $3.25
- Shares out
- 32,838,000
- Stochastic %K
- 11%
- Beta
- 0.38
- Analysts
- Hold
- Price target
- $6.00
Company profile
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its...
Show more
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 369 7100
- Website
- https://meipharma.com
- Address
- 9920 Pacific Heights Blvd., Suite 150, San Diego, United States
Latest news
No headlines yet.
